Lonza Group AG (LZAGF)
USD 588.7
(0.0%)
USD 588.7
(0.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 6.71 Billion CHF | 7.94% |
| 2022 | 6.22 Billion CHF | 15.05% |
| 2021 | 5.4 Billion CHF | 19.99% |
| 2020 | 4.5 Billion CHF | -23.85% |
| 2019 | 5.92 Billion CHF | 6.82% |
| 2018 | 5.54 Billion CHF | 8.56% |
| 2017 | 5.1 Billion CHF | 23.55% |
| 2016 | 4.13 Billion CHF | 8.65% |
| 2015 | 3.8 Billion CHF | 4.48% |
| 2014 | 3.64 Billion CHF | 1.56% |
| 2013 | 3.58 Billion CHF | -8.69% |
| 2012 | 3.92 Billion CHF | 45.8% |
| 2011 | 2.69 Billion CHF | 0.45% |
| 2010 | 2.68 Billion CHF | -0.37% |
| 2009 | 2.69 Billion CHF | -8.41% |
| 2008 | 2.93 Billion CHF | 2.33% |
| 2007 | 2.87 Billion CHF | 25.6% |
| 2006 | 2.28 Billion CHF | -9.36% |
| 2005 | 2.52 Billion CHF | 15.54% |
| 2004 | 2.18 Billion CHF | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 1.52 Billion CHF | 0.0% |
| 2024 Q1 | 1.52 Billion CHF | -58.0% |
| 2023 Q2 | 3.07 Billion CHF | 100.0% |
| 2023 Q1 | 1.53 Billion CHF | -52.51% |
| 2023 Q3 | 1.81 Billion CHF | -40.89% |
| 2023 FY | 6.71 Billion CHF | 7.94% |
| 2023 Q4 | 3.63 Billion CHF | 100.0% |
| 2022 Q3 | 1.62 Billion CHF | -45.66% |
| 2022 Q4 | 3.24 Billion CHF | 100.0% |
| 2022 FY | 6.22 Billion CHF | 15.05% |
| 2022 Q1 | 1.49 Billion CHF | -47.99% |
| 2022 Q2 | 2.98 Billion CHF | 100.0% |
| 2021 Q4 | 2.86 Billion CHF | 100.0% |
| 2021 Q3 | 1.43 Billion CHF | -43.61% |
| 2021 Q2 | 2.54 Billion CHF | 100.0% |
| 2021 Q1 | 1.27 Billion CHF | -11.37% |
| 2021 FY | 5.4 Billion CHF | 19.99% |
| 2020 Q3 | 1.13 Billion CHF | -63.16% |
| 2020 FY | 4.5 Billion CHF | -23.85% |
| 2020 Q4 | 1.43 Billion CHF | 26.62% |
| 2020 Q1 | 1.12 Billion CHF | -61.91% |
| 2020 Q2 | 3.07 Billion CHF | 174.1% |
| 2019 Q3 | 1.47 Billion CHF | -1.08% |
| 2019 FY | 5.92 Billion CHF | 6.82% |
| 2019 Q4 | 2.94 Billion CHF | 100.0% |
| 2019 Q1 | 1.48 Billion CHF | 8.38% |
| 2019 Q2 | 1.48 Billion CHF | 0.0% |
| 2018 FY | 5.54 Billion CHF | 8.56% |
| 2018 Q3 | 1.37 Billion CHF | -1.79% |
| 2018 Q2 | 1.39 Billion CHF | 0.0% |
| 2018 Q1 | 1.39 Billion CHF | 65.05% |
| 2018 Q4 | 1.37 Billion CHF | 0.0% |
| 2017 FY | 5.1 Billion CHF | 23.55% |
| 2017 Q2 | 1.15 Billion CHF | 0.0% |
| 2017 Q1 | 1.15 Billion CHF | 9.32% |
| 2017 Q3 | 1.39 Billion CHF | 20.43% |
| 2017 Q4 | 847 Million CHF | -39.11% |
| 2016 FY | 4.13 Billion CHF | 8.65% |
| 2016 Q2 | 1 Billion CHF | 0.0% |
| 2016 Q1 | 1 Billion CHF | 6.32% |
| 2016 Q4 | 1.05 Billion CHF | 0.0% |
| 2016 Q3 | 1.05 Billion CHF | 4.66% |
| 2015 Q2 | 952 Million CHF | 0.0% |
| 2015 FY | 3.8 Billion CHF | 4.48% |
| 2015 Q3 | 949.5 Million CHF | -0.26% |
| 2015 Q1 | 952 Million CHF | 3.48% |
| 2015 Q4 | 949.5 Million CHF | 0.0% |
| 2014 Q2 | 900 Million CHF | 0.0% |
| 2014 Q1 | 900 Million CHF | -2.17% |
| 2014 FY | 3.64 Billion CHF | 1.56% |
| 2014 Q4 | 920 Million CHF | 0.0% |
| 2014 Q3 | 920 Million CHF | 2.22% |
| 2013 Q3 | 920 Million CHF | 5.5% |
| 2013 FY | 3.58 Billion CHF | -8.69% |
| 2013 Q1 | 872 Million CHF | 0.0% |
| 2013 Q4 | 920 Million CHF | 0.0% |
| 2013 Q2 | 872 Million CHF | 0.0% |
| 2012 FY | 3.92 Billion CHF | 45.8% |
| 2011 FY | 2.69 Billion CHF | 0.45% |
| 2010 FY | 2.68 Billion CHF | -0.37% |
| 2009 FY | 2.69 Billion CHF | -8.41% |
| 2008 FY | 2.93 Billion CHF | 2.33% |
| 2007 FY | 2.87 Billion CHF | 25.6% |
| 2006 FY | 2.28 Billion CHF | -9.36% |
| 2005 FY | 2.52 Billion CHF | 15.54% |
| 2004 FY | 2.18 Billion CHF | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| American Bio Medica Corporation | 913 Thousand USD | -735606.462% |
| Arrayit Corporation | 4.37 Million USD | -153350.757% |
| Atlantic International Corp. | - USD | -Infinity% |
| Biocept, Inc. | 25.85 Million USD | -25876.487% |
| Bioqual, Inc. | 58.59 Million USD | -11364.228% |
| CardioGenics Holdings Inc | - USD | -Infinity% |
| DermTech, Inc. | 15.29 Million USD | -43813.441% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 7.38 Billion USD | 9.034% |
| HTG Molecular Diagnostics, Inc. | 6.36 Million USD | -105410.02% |
| iMD Companies, Inc. | - USD | -Infinity% |
| IDenta Corp. | 1.05 Million USD | -638647.04% |
| Interpace Biosciences, Inc. | 40.21 Million USD | -16603.138% |
| Integrative Health Technologies, Inc. | 447.49 Thousand USD | -1500908.941% |
| InVitro International | 792.62 Thousand USD | -847334.105% |
| Lumos Diagnostics Holdings Limited | 11.13 Million USD | -60244.982% |
| Many Bright Ideas Technologies Inc. | - USD | -Infinity% |
| Medical Imaging Corp. | 7.22 Million USD | -92878.819% |
| NovelStem International Corp. | 12 Thousand USD | -55974900.0% |
| Optigenex Inc. | 465.97 Thousand USD | -1441409.11% |
| PharmChem, Inc. | 6.01 Million USD | -111619.058% |
| Proteome Sciences plc | 6.4 Million USD | -104842.565% |
| Response Genetics, Inc | 18.04 Million USD | -37133.925% |
| Rennova Health, Inc. | 13.03 Million USD | -51425.862% |
| RushNet, Inc. | 1.78 Million USD | -375596.355% |
| ScreenPro Security Inc. | 1.91 Million USD | -350821.554% |
| Stella Diagnostics Inc. | - USD | -Infinity% |
| StageZero Life Sciences Ltd. | 3.79 Million USD | -176892.503% |
| Todos Medical Ltd. | 7.69 Million USD | -87190.448% |